Survival of infants born with esophageal atresia among 24 international birth defects surveillance programs.
congenital anomalies
esophageal atresia
infant
mortality
survival
Journal
Birth defects research
ISSN: 2472-1727
Titre abrégé: Birth Defects Res
Pays: United States
ID NLM: 101701004
Informations de publication
Date de publication:
15 07 2021
15 07 2021
Historique:
revised:
07
03
2021
received:
06
02
2021
accepted:
08
03
2021
pubmed:
19
3
2021
medline:
3
11
2021
entrez:
18
3
2021
Statut:
ppublish
Résumé
Esophageal atresia (EA) affects around 2.3-2.6 per 10,000 births world-wide. Infants born with this condition require surgical correction soon after birth. Most survival studies of infants with EA are locally or regionally based. We aimed to describe survival across multiple world regions. We included infants diagnosed with EA between 1980 and 2015 from 24 birth defects surveillance programs that are members of the International Clearinghouse for Birth Defects Surveillance and Research. We calculated survival as the proportion of liveborn infants alive at 1 month, 1- and 5-years, among all infants with EA, those with isolated EA, those with EA and additional anomalies or EA and a chromosomal anomaly or genetic syndrome. We also investigated trends in survival over the decades, 1980s-2010s. We included 6,466 liveborn infants with EA. Survival was 89.4% (95% CI 88.1-90.5) at 1-month, 84.5% (95% CI 83.0-85.9) at 1-year and 82.7% (95% CI 81.2-84.2) at 5-years. One-month survival for infants with isolated EA (97.1%) was higher than for infants with additional anomalies (89.7%) or infants with chromosomal or genetic syndrome diagnoses (57.3%) with little change at 1- and 5-years. Survival at 1 month improved from the 1980s to the 2010s, by 6.5% for infants with isolated EA and by 21.5% for infants with EA and additional anomalies. Almost all infants with isolated EA survived to 5 years. Mortality was higher for infants with EA and an additional anomaly, including chromosomal or genetic syndromes. Survival improved from the 1980s, particularly for those with additional anomalies.
Sections du résumé
BACKGROUND
Esophageal atresia (EA) affects around 2.3-2.6 per 10,000 births world-wide. Infants born with this condition require surgical correction soon after birth. Most survival studies of infants with EA are locally or regionally based. We aimed to describe survival across multiple world regions.
METHODS
We included infants diagnosed with EA between 1980 and 2015 from 24 birth defects surveillance programs that are members of the International Clearinghouse for Birth Defects Surveillance and Research. We calculated survival as the proportion of liveborn infants alive at 1 month, 1- and 5-years, among all infants with EA, those with isolated EA, those with EA and additional anomalies or EA and a chromosomal anomaly or genetic syndrome. We also investigated trends in survival over the decades, 1980s-2010s.
RESULTS
We included 6,466 liveborn infants with EA. Survival was 89.4% (95% CI 88.1-90.5) at 1-month, 84.5% (95% CI 83.0-85.9) at 1-year and 82.7% (95% CI 81.2-84.2) at 5-years. One-month survival for infants with isolated EA (97.1%) was higher than for infants with additional anomalies (89.7%) or infants with chromosomal or genetic syndrome diagnoses (57.3%) with little change at 1- and 5-years. Survival at 1 month improved from the 1980s to the 2010s, by 6.5% for infants with isolated EA and by 21.5% for infants with EA and additional anomalies.
CONCLUSIONS
Almost all infants with isolated EA survived to 5 years. Mortality was higher for infants with EA and an additional anomaly, including chromosomal or genetic syndromes. Survival improved from the 1980s, particularly for those with additional anomalies.
Identifiants
pubmed: 33734618
doi: 10.1002/bdr2.1891
pmc: PMC8273078
mid: NIHMS1684911
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
945-957Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Organisme : NCBDD CDC HHS
ID : U01 DD001285
Pays : United States
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Reprod Toxicol. 1993 Sep-Oct;7(5):405-21
pubmed: 8274816
J Med Genet. 2006 Jul;43(7):545-54
pubmed: 16299066
J Pediatr Surg. 2006 Feb;41(2):331-4
pubmed: 16481246
Lancet. 2010 Feb 20;375(9715):649-56
pubmed: 20092884
Pediatr Surg Int. 2012 Mar;28(3):249-57
pubmed: 22020495
J Pediatr Surg. 2013 Aug;48(8):1664-9
pubmed: 23932604
Br J Surg. 2013 Mar;100(4):515-21
pubmed: 23334932
Teratology. 2001 Nov;64(5):267-75
pubmed: 11745833
Arch Dis Child. 2012 Mar;97(3):227-32
pubmed: 22247246
Birth Defects Res. 2017 Nov 1;109(18):1504-1514
pubmed: 29152924
Birth Defects Res A Clin Mol Teratol. 2011 Dec;91(12):995-1003
pubmed: 21960515
Am J Public Health. 2014 Sep;104(9):e14-23
pubmed: 25033129
Pediatrics. 2003 Apr;111(4 Pt 1):777-84
pubmed: 12671111
Surgery. 2014 Aug;156(2):483-91
pubmed: 24947650
J Surg Res. 2014 Aug;190(2):604-12
pubmed: 24881472
J Pediatr. 2015 Apr;166(4):819-26.e1-2
pubmed: 25641238
Arch Dis Child. 2003 May;88(5):391-4
pubmed: 12716706
Birth Defects Res A Clin Mol Teratol. 2016 Jul;106(7):542-8
pubmed: 26931365
Birth Defects Res A Clin Mol Teratol. 2012 Nov;94(11):893-9
pubmed: 22945024